Complete List of Activities 2020
| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| Tobacco Use Supplement to Current Population Survey | Health Survey | CDC, FDA | NCI, NIMHD | The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an National Cancer Institute (NCI)-sponsored survey of tobacco use that has been administered as part of the US Census Bureau's Current Population Survey approximately every 3-4 years since 1992-93. |
| Tox 21 | Resource Development | FDA | NCATS, NIEHS | The Toxicology in the 21st Century (Tox21) program is a federal collaboration among National Institutes of Health(NIH) National Center for Advancing Translational Science (NCATS) and the National Toxicology Program at the National Institute of Environmental Health Sciences; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects. |
|
Toxicology in the 21st Century Federal Consortium NTP – NCATS Interagency Agreement, ES-7020-01, Year 11 (Tox21) |
Other | FDA | NIEHS, NCATS | Tox21 is a US federal research collaboration focused on driving the evolution of Toxicology in the 21st Century by developing methods to rapidly and efficiently evaluate the safety of commercial chemicals, pesticides, food additives/contaminants, and medical products. This IAA is designed to explore new, effective, primarily non-animal methods and technologies to elucidate critically important questions pertaining to impacts of environmental exposures on cellular toxicity pathways that may lead to human disease. A major focus is the development of innovative approaches in toxicology assessment. |
| Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.” |
| Toxins Assessment Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons |
| Training Advisory Committee (TAC) | Committee, Work group, Advisory group, or Task Force | AHRQ | OD/OER, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP | The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development and diversity programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides a trans-NIH forum to identify and discuss issues related to these programs and recommend solutions. |
| Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation. |
| Trans-National Institutes of Health (NIH) Tuberculosis (TB) Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, FIC, NCATS, NCI, NHLBI, NIAAA, NIAID, NIDA, NIGMS, OD/DPCPSI/OAR | The TB Working Group provides a forum for sharing information about NIH-specific TB projects, including both ongoing and proposed research, including extramural funding initiatives. In addition, the working group fosters continual open communication about TB research being conducted across NIH and maintains a consistent message about the importance of NIH intramural and extramural TB research. It also provides an avenue for the introduction of new technology programs of interest and importance for TB research (such as the "human on a chip"). The working group invites guests/speakers from outside NIH and convenes invitations for teleconference participation to other US Government agencies including the Centers for Disease Control and Prevention (CDC) and the US Agency for International Development (USAID). |
| Trans-NIH Structural Birth Defects Working Group (SBDWG) | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCD, NIDCR, NIDDK, NIEHS, NINDS | The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects. |
| Trans-NIH Working Group for Objective Measures in Cancer | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIBIB, NIDDK | An National Institutes of Health (NIH) working group was formed to develop and consolidate wearable, passive and continuous out-of-clinic monitoring strategies for clinical assessment and understanding of disease progression in cancer. The goal of this group and its activities is to examine how these devices and techniques can be used to assess and understand cancer progression from multi-parameter data (context, vitals, and/or chemistry). Currently, several non-HHS agencies (National Institute of Standards and Technology (NIST), Department of Defense (DoD), Department of Energy (DOE), the National Aeronautics and Space Administration (NASA) and HHS agencies (NIH and the Food and Drug Administration) are also involved in these discussions and will integrate their expertise/mission to propagate for medical purposes. |